Pharmaceutical Industry Information Portal


All posts by tag


FDA Approves alpelisib as first and only treatment for PROS, a spectrum of rare conditions

Novartis on Wednesday announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and...

Novartis changes organizational structure to save at least $1 billion by 2024

Novartis today announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity ambitions as...

Novartis targeted radiation therapy gets FDA nod for PSMA

Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™(lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with...

Sandoz bolsters respiratory ambitions with the acquisition of Coalesce

Sandoz, a Novartis division, announced today that it has successfully acquired the UK-based medical and drug delivery device development company, Coalesce Product Development Limited. Coalesce...

Novartis and Voyager Therapeutics announce partnership to develop next-generation gene therapy for neurological diseases

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids...

AGC Biologics Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities

AGC Biologics announced the signing of a purchase agreement for a state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, currently owned by Novartis Gene Therapies.

Expert Articles